Avalo Therapeutics
AVTX
13.58
-0.01
-0.07%
Avalo Therapeutics
US · AVTX
#3484 by market cap
13.58
-0.01
-0.07%
Live - 5344 symbols - heartbeat 164s ago
· 2026-10-08 08:02
Pre-market
14.14
+4.12%
After-hours
13.58
0.00%
- Market cap
- 728.30M
- P/E (TTM)i
- -3.08
- P/Bi
- 1.62
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 9%
Reader sentiment
Are you bullish or bearish on AVTX?
Anonymous reader poll. Unscientific, not investment advice.
About Avalo Therapeutics
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
- Founded
- 2011
- CEO
- Dr. Garry A. Neil, M.D.
- Employees
- 33
- Headquarters
- Wayne, Pennsylvania, United States of America
- Fiscal year end
- 12-31
- Website
- avalotx.com
Company profile
- Exchange
- US
- Symbol
- AVTX
- Market-cap rank
- #3484
- Market cap
- 728.30M
- Float cap
- 544.70M
- Shares out
- 53.63M
- Float shares
- 40.11M
Sectors & themes
Biotechnology
Quote time 2026-10-08 08:02:58 · For reference only, not investment advice and not tailored to your situation.